Ovarian cancer is the fifth leading cause of cancer-related death in women and represents one of the most challenging problems in women's health.[1] About 75% of cases are diagnosed at an advanced stage (3–4), when the prognosis is poor and treatment options have limited efficacy.[1] The late stage of the disease results from two key factors: the early spread of the tumor in the peritoneal cavity and the absence of specific symptoms or effective screening tools.[1] The Lancet Commission on Ovarian Cancer represents a bold and necessary initiative to address this problem through coordinated global action for action-led reform.[1] A recent LMIC Every Woman Study™ involving 2,446 women from 82 hospitals in 22 low- and middle-income countries showed that 90% of women experienced at least one symptom associated with ovarian cancer before diagnosis, and that nearly a third of women saw their family income drop below subsistence levels.[1]